BioNTech’s ‘extensive’ cancer pipeline comes into focus, with emphasis on ADCs
BioNTech, one of the biotech startups that helped vaccinate billions of people around the world against Covid-19, is starting to look like a cancer company.
The company’s executives spent four hours running through their cancer programs at BioNTech’s Innovation Day on Tuesday, discussing data from a variety of antibody-drug conjugates, bispecifics, CAR-Ts and cancer vaccines. The event marked an effort to crystallize how BioNTech’s recent dealmaking spree is coming together as Covid-19 continues to shift to an endemic disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.